

Keywords: *BRCA1* germline mutations; constitutional mosaicism; breast cancer predisposition; deep sequencing

Low-level constitutional mosaicism of a *de novo* *BRCA1* gene mutation

E Friedman^{*1,2}, N Efrat³, L Soussan-Gutman⁴, A Dvir⁴, Y Kaplan⁴, T Ekstein⁵, K Nykamp⁵, M Powers⁵, M Rabideau⁵, J Sorenson⁵ and S Topper⁵

¹The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center at Tel-Hashomer, Tel-Aviv 5262100, Israel; ²Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, 5262100, Israel; ³Department of Oncology, Kaplan Medical Center, Rehovot, Israel; ⁴Oncotest-Teva, Teva Pharmaceuticals Industries, Petach Tikva 49510, Israel and ⁵Invitae Corp., San Francisco, California 94107, USA

Background: Pathogenic *BRCA1* mutations are usually inherited. Constitutional low-level *BRCA1* mosaicism has never been reported.

Methods: Next-generation sequencing (NGS) of cancer gene panel of germline and tumour DNA in a patient with early onset, triple-negative breast cancer.

Results: Constitutional *de novo* mosaicism (5%) for a pathogenic (c.1953dupG; p.Lys652Glufs*21) *BRCA1* mutation was detected in leukocytes, buccal tissue and normal breast tissue DNA, with ~50% mutation in tumorous breast tissue.

Conclusion: This is the first reported case of low-level, multiple tissue, constitutional mosaicism in *BRCA1*, and highlights the need to consider deep sequencing in affected individuals clinically suspected of having cancer predisposition whose tumours display a *BRCA* mutation.

Heterozygous germline mutations in the *BRCA1* and *BRCA2* (MIM *113705*600185) genes detected in a subset of high-risk breast/ovarian families are used clinically to objectively assess lifetime risks for developing these and other cancer types, and can have an impact on recommendations for early detection and risk-reducing surgeries (Petrucci *et al*, 2010). DNA sequencing of the tumour tissue can be used to detect somatic mutations that may define therapeutic targets and refine treatment options (Ross *et al*, 2013; Ali *et al*, 2014). However, a third case is rarely considered – somatic mutations in either gene acquired early in embryonic development, which establish a predisposition for disease but which are not detected by traditional sequencing technologies. The gold standard for detecting *BRCA* genes' sequence variants has long been Sanger sequencing, but recently next-generation sequencing (NGS) technologies have emerged as a highly accurate and efficient alternative (Feliubadalo *et al*, 2013; Kurian *et al*, 2014), with improved sensitivity for detection of mosaic events. Here we describe the occurrence of very low-level constitutional

mosaicism of a pathogenic *BRCA1* gene mutation and the possible implications of this novel finding.

MATERIALS AND METHODS

All mutation analyses were performed using an ethically approved protocol, subsequent to informed consent. NGS of 29 hereditary cancer genes in DNA extracted from the blood was performed at Invitae (San Francisco, CA, USA), a clinical laboratory improvement amendments-approved laboratory, using Invitae's Hereditary Cancer Panel (Kurian *et al*, 2014). The tested genes included *APC*, *ATM*, *BMPRIA*, *BRCA1*, *BRCA2*, *BRIPI*, *CDH1*, *CDK4*, *CDKN2A*, *CHEK2*, *EPCAM*, *MEN1*, *MET*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PALLD*, *PMS2*, *PTCH1*, *PTEN*, *RAD51C*, *RET*, *SMAD4*, *STK11*, *TP53* and *VHL*. Targeted genes were captured from genomic DNA extracted from whole blood using SureSelect

*Correspondence: Professor E Friedman; E-mail: eitan.friedman@sheba.health.gov.il or eitan211@netvision.net.il

Received 26 November 2014; revised 24 December 2014; accepted 30 December 2014; published online 29 January 2015

© 2015 Cancer Research UK. All rights reserved 0007–0920/15

probes (Agilent, Santa Clara, CA, USA) or xGen Lockdown probes (Integrated DNA Technologies, Coral, IL, USA). Next-generation DNA sequencing (NGS) was carried out on the MiSeq or HiSeq 2500 platform (Illumina, San Diego, CA, USA) to a minimum of $50 \times$ required to report an alteration at any site. Sequence reads were aligned against the reference human genome sequence and sequence variants (single-nucleotide changes, insertions and deletions), as well as copy number variants (deletions and duplications), and were called from the NGS data. Sequence analysis was performed for all targeted genes and copy number analysis was performed for all genes except *CHEK2*, *PALLD* and *MET*. Procedures were implemented to ensure adequate NGS coverage and quality over the targeted genes, to detect sample swaps and to detect sample cross-contamination.

Somatic analysis was performed using a test based on massively parallel DNA sequencing across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded clinical specimens, both from the breast tumour and the healthy breast tissue (Foundation Medicine, Cambridge, MA, USA). Reference samples of pooled cell lines that model key determinants of accuracy, including mutant allele frequency, indel length and amplitude of copy change. The percentage of reads with the alteration was communicated by e-mail.

RESULTS

Case report. The proband, a Jewish woman of mixed Ashkenazi (paternal) and Bulgarian (maternal) origin was diagnosed with a large (8×10 cm), triple-negative, high-grade, high ki67 (60%), invasive unilateral breast cancer at age 43 years. Her family history pertaining to cancer included a daughter with acute lymphatic leukemia at age 18 months, a brother with a CNS tumour at age 45 years, a father with a malignant CNS tumour at age 58 years, a maternal grandfather with a malignant tumour of unknown pathological features in his 70s and two of this maternal grandfather's sisters who were diagnosed with breast cancer at unknown ages. The patient was treated with standard neoadjuvant chemotherapy consisting of four cycles of doxorubicin/cyclophosphamide and 12 weekly cycles of paclitaxel and carboplatin. Neoadjuvant chemotherapy was followed by bilateral mastectomy (therapeutic mastectomy and contralateral, risk-reducing mastectomy) and reconstruction. At surgery, residual tumour was evident and was followed by chest and lymphatic region irradiation. Pathologically confirmed, triple-negative breast cancer recurred in the reconstructed breast and in the contralateral reconstructed breast 3 months after radiotherapy. Systemic treatment with bevacizumab and capecitabine was followed by

gemcitabine/cisplatin with minimal, short lasting response. The patient died 15 months after initial diagnosis.

Genetic analyses. Next-generation DNA sequencing of 29 hereditary cancer genes in DNA extracted from the blood identified a pathogenic *BRCA1* mutation in 5% of reads ($\sim 3000 \times$ at this locus): c.1953dupG (NM_007294.3), which leads to a lysine to glutamine alteration in codon 652 and a premature stop codon 21 amino acids downstream (p.Lys652Glnfs*21). No other pathogenic mutations were detected in any of the other analysed cancer susceptibility genes. A second independent blood draw and a buccal swab were also tested at Invitae (and blood draw 1 was tested again, to establish technical reproducibility) and a mosaic signal of 4.9%–6.8% was reproducibly detected in all samples. Earlier, Sanger sequencing of *BRCA1* and *BRCA2* in DNA extracted from peripheral blood, performed as part of the routine clinical workup at a different commercial lab, had not detected this mutation. However, careful evaluation of this locus in confirmatory Sanger sequence at Invitae did demonstrate the presence of a small peak (Figure 1). Interestingly, tumour tissue from the right breast was sequenced by a commercially available somatic NGS assay (Frampton *et al*, 2013) and the same mutation, c.1943dupG, was detected in 47% of sequence reads ($> 500 \times$ coverage). The mutation was also detected in 5% of reads derived from normal tissue from the histopathologically normal left breast. Together, these results confirm that this individual is a constitutional mosaic for this mutation (Table 1). Analysis of the maternal peripheral blood DNA using the Invitae deep-sequencing platform demonstrated the absence of this mutation.

Notably, for normal tissue samples, the percentage of cells that are heterozygous for the mutation is twice the percentage of sequence reads that carry the insertion. For tumour cells, the observed percentage of affected sequence reads depends on the homogeneity of the biopsy and may be confounded by acquired deletions on the opposite allele; thus, the percentage of cells carrying this mutation on one chromosome cannot be accurately estimated.

The c.1953dupG *BRCA1* mutation is 129 bp away from a common SNP (c.2082C>T; rs1799949), which is also absent in the maternal DNA sample, indicating that the SNP identifies the paternally inherited allele. An analysis of reads spanning both positions (c.1953 and c.2082) identifies sequence reads containing both variants, indicating that the c.1953dupG mutation is in *cis* with the c.2082 variant and is on the paternal allele. This analysis also identifies the presence of reads containing the c.2082 variant and not the c.1953dupG mutation, a finding indicating that the c.1953dupG mutation was not inherited, but was acquired post fertilisation.




Figure 1. Data supporting mosaic mutation. (A) A visualisation of NGS data from blood draw 1, extraction 1. Reads carrying the c.1953dupG insertion are indicated with the purple line. (B) Sanger-sequence data confirming the presence of the c.1953dupG mutation in a portion of cells. The signal is almost indistinguishable from background noise. Reference sequence indicates the positive strand.

Table 1. Mutational load in different tissues

Tissue	Reads indicating insertion	Total depth at this position	% Reads carrying the insertion	% Heterozygous cells
Blood (draw 1, extraction 1)	164	3307	5.0	9.9
Blood (draw 1, extraction 2)	143	2889	4.9	9.9
Blood (draw 2)	127	2460	5.2	10.3
Buccal swab	149	2207	6.8	13.5
Normal breast tissue	–	–	5.0	10.0
Breast tumour	–	–	47.0	Uncertain

DISCUSSION

This case represents the first report of a very low-level constitutional mosaic pathogenic *BRCA1* mutation. NGS studies of DNA extracted from three normal tissues (blood, buccal swab and normal breast tissue) detected the pathogenic variant in ~5% of reads, while sequencing of tumour tissue detected the pathogenic variant in ~50% of reads. These data confirm that this individual is a constitutional mosaic for this mutation and suggest strongly that this mutation is driving tumour development in this individual. Alternative explanations for this finding (circulating tumour cells, technical error and somatic mosaicism in the tumour alone) have been ruled out by identifying the same sequence change in two independent blood samples, in buccal tissue and in non-cancerous breast tissue at approximately the same detection levels. In previous reports of somatic *BRCA1* mutations, only tumour cells harboured the mutant allele (Takahashi *et al*, 1995; Welch and King, 2001; Janatova *et al*, 2005; Zhang *et al*, 2012).

The mutation in this individual had been missed in a clinical, Sanger-based sequencing assay of *BRCA1* and *BRCA2* of DNA extracted from the blood, as Sanger sequencing, in general, cannot reliably detect a mutation present at a load of <20% (Rohlin *et al*, 2009). This case illustrates the need to possibly consider genetic testing by applying deep-sequencing methodology in individuals whose clinical features are suggestive of a genetic predisposition, whose tumours show a *BRCA* mutation that cannot be confirmed with standard Sanger sequencing. In this case, the genetic predisposition was highlighted by an early age of onset, a triple-negative tumour (Gonzalez-Angulo *et al*, 2011) and breast cancer diagnosed in the contralateral breast within a few months after the initial diagnosis. Notably, family history is non-contributory, as the closest relatives with *BRCA1*-related tumours are third-degree relatives on the maternal side (the maternal grandfather's sisters) and the mother does not carry the mutation, and the mutant allele is paternally inherited, although the family history on the paternal side is not consistent with a *BRCA1* phenotype.

A few cases of *de novo* constitutional *BRCA1* or *BRCA2* have previously been described, but most were detected in a heterozygous form in constitutional DNA and were not mosaic (Tesoriero *et al*, 1999; Robson *et al*, 2002; Hansen *et al* 2008; Edwards *et al*, 2009; Marshall *et al*, 2009; Garcia-Casado *et al*, 2011; Kwong *et al*, 2011; Zhang *et al*, 2011) or detected at a high frequency of >70% of cells (Delon *et al*, 2013). The per cent of hereditary breast ovarian cancer cases that can be attributed to low-level constitutional mosaicism is not known at this time.

This case demonstrates conclusively that low-level constitutional mosaicism for pathogenic mutations in *BRCA1* can be a cause of early-onset breast cancer, and the consistency of the load across tissue types suggests that this event occurred early in embryonic development. This notion is further supported by the lack of the same mutation in maternal constitutional DNA using deep sequencing. This case may offer new insights into clinical

decision-making regarding genetic testing for breast cancer cases, and further expansion to explore the extent of the phenomenon is warranted. It also seems that NGS sequencing should be considered and discussed with affected individuals whose tumours display a *BRCA* mutation that cannot be demonstrated using Sanger sequencing. It seems that constitutional mosaics for a pathogenic mutation in *BRCA1* similar to constitutional heterozygous mutation carriers should be counselled as to their own risk for contralateral breast cancer, ovarian cancer and cancer risks for their offspring.

ACKNOWLEDGEMENTS

We thank the patient and the patient's family, as well as everyone who performed the genetic testing and analysed the data.

CONFLICT OF INTEREST

TE, KN, MP, MR, JS and ST are employed by the InVita Corporation; LS-G, AD and YK are all employed by OncotestTeva, the distributor of InVita in Israel. EF and NE declare no conflict of interest.

REFERENCES

- Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofani M (2014) Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. *Clin Breast Cancer* **14**(1): e14–e16.
- Delon I, Taylor A, Molenda A, Drummond J, Oakhill K, Girling A, Liu H, Whittaker J, Treacy R, Tischkowitz M (2013) A germline mosaic *BRCA1* exon deletion in a woman with bilateral basal-like breast cancer. *Clin Genet* **84**(3): 297–299.
- Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D (2009) Identification of a *de novo* *BRCA1* mutation in a woman with early onset bilateral breast cancer. *Fam Cancer* **8**(4): 479–482.
- Feliubadalo L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, Tornero E, Montes E, Cuesta R, Gómez C, Campos O, Pineda M, González S, Moreno V, Brunet J, Blanco I, Serra E, Capellá G, Lázaro C (2013) Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of *BRCA1* and *BRCA2* genes. *Eur J Hum Genet* **21**(8): 864–870.
- Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Puzstai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol* **31**(11): 1023–1031.

- Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, Llombart P, Lopez-Guerrero JA (2011) A *de novo* complete *BRCA1* gene deletion identified in a Spanish woman with early bilateral breast cancer. *BMC Med Genet* **12**: 134–143.
- Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of *BRCA* mutations in unselected patients with triple receptor-negative breast cancer. *Clin Cancer Res* **17**(5): 1082–1089.
- Hansen TV, Bisgaard ML, Jonson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, Ejlersten B, Nielsen FC (2008) Novel *de novo* *BRCA2* mutation in a patient with a family history of breast cancer. *BMC Med Genet* **9**: 58–67.
- Janatova M, Zikan M, Dundr P, Matous B, Pohlreich P (2005) Novel somatic mutations in the *BRCA1* gene in sporadic breast tumors. *Hum Mutat* **25**(3): 319.
- Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE, Cargill M, Ford JM (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol* **32**(19): 2001–2009.
- Kwong A, Ng EK, Tang EY, Wong CL, Law FB, Leung CP, Chan A, Cheung MT, To MY, Ma ES, West DW, Ford JM (2011) A novel *de novo* *BRCA1* mutation in a Chinese woman with early onset breast cancer. *Fam Cancer* **10**(2): 233–237.
- Marshall M, Solomon S, Lawrence Wickerham D (2009) Case report: *de novo* *BRCA2* gene mutation in a 35-year-old woman with breast cancer. *Clin Genet* **76**(5): 427–430.
- Petrucelli N, Daly MB, Feldman GL (2010) Hereditary breast and ovarian cancer due to mutations in *BRCA1* and *BRCA2*. *Genet Med* **12**(5): 245–259.
- Robson M, Scheuer L, Nafa K, Ellis N, Offit K (2002) Unique *de novo* mutation of *BRCA2* in a woman with early onset breast cancer. *J Med Genet* **39**(2): 126–128.
- Rohlin A, Wernersson J, Engwall Y, Wiklund L, Bjork J, Nordling M (2009) Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. *Hum Mutat* **30**(6): 1012–1020.
- Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ (2013) Relapsed classic E-cadherin (*CDH1*)-mutated invasive lobular breast cancer shows a high frequency of *HER2* (*ERBB2*) gene mutations. *Clin Cancer Res* **19**(10): 2668–2676.
- Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, Menzin AW, Liu PC, Benjamin I, Morgan MA, King SA, Rebane BA, Cardonick A, Mikuta JJ, Rubin SC, Boyd J (1995) Mutation analysis of the *BRCA1* gene in ovarian cancers. *Cancer Res* **55**(14): 2998–3002.
- Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D (1999) *De novo* *BRCA1* mutation in a patient with breast cancer and an inherited *BRCA2* mutation. *Am J Hum Genet* **65**(2): 567–569.
- Welch PL, King MC (2001) *BRCA1* and *BRCA2* and the genetics of breast and ovarian cancer. *Hum Mol Genet* **10**(7): 705–713.
- Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK, Kauff ND, Offit K, Robson ME (2011) Assessment of the prevalence of *de novo* mutations in the *BRCA1* and *BRCA2* genes. *Clin Genet* **80**(1): 97–98.
- Zhang M, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Lin B, Xie Y (2012) Somatic mutations in the *BRCA1* gene in Chinese women with sporadic breast cancer. *Breast Cancer Res Treat* **132**(1): 335–340.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.